Advances in the Impact of Microbial Dissemination in Metabolic Fatty Liver Disease through the Oral-gut-liver Axis Theory

doi:10.12114/j.issn.1007-9572.2023.0633

Abstract

Abstract:

Metabolic fatty liver disease (MAFLD) is one of the most common chronic liver diseases worldwide, with a prevalence of up to 30% in China, and still rising. The disease is associated with genetic factors, environmental factors and patients' lifestyle habits, and is easily combined with various metabolism-related diseases such as diabetes, cardiovascular and cerebral vascular diseases, as well as serious complications such as liver cirrhosis and liver cancer. An increasing number of basic experimental and clinical studies have demonstrated the relevance of oral and gut microbiota to MAFLD, and targeted treatment of oral and gut microbiota may play an important role in the prevention and treatment of MAFLD. In this paper, we summarize the oral and gut microbiota characteristics of MAFLD patients based on the theory of the oral-gut-liver axis and the mechanism of the role of oral and gut microbiota dysbiosis on the development of MAFLD, hoping to provide ideas for the diagnosis and treatment of MAFLD.

Key words: MAFLD, Oral-gut-liver axis, Microbiota, Review

摘要：

代谢相关脂肪性肝病（MAFLD）是世界范围内常见的慢性肝病之一，中国患病率高达30%，且仍在不断上升。MAFLD的发病与遗传因素、环境因素及患者不良生活习惯等原因密切相关，易合并糖尿病、心脑血管疾病等多种代谢相关性疾病，可能发生肝硬化、肝癌等严重并发症。越来越多的基础实验和临床研究证明了口腔和肠道微生物群与MAFLD的相关性，对口腔和肠道微生物组的靶向治疗可能在预防和治疗MAFLD上发挥重要作用。本文基于口-肠-肝轴理论总结了MAFLD患者的口肠微生物群特征与口肠微生物群失调对MAFLD发生、发展的作用机制，探讨了基于口肠微生物群治疗MAFLD的方式，以期为临床MAFLD的诊断与治疗提供思路。

关键词: 代谢相关脂肪性肝病, 口-肠-肝轴, 微生物群, 综述

CLC Number:

R 256.4

HAO Qi,LU Chenxia,LI Xiaodong. Advances in the Impact of Microbial Dissemination in Metabolic Fatty Liver Disease through the Oral-gut-liver Axis Theory[J]. Chinese General Practice, 2024, 27(26): 3320-3324. DOI: 10.12114/j.issn.1007-9572.2023.0633.
郝琦,卢晨霞,李晓东. 基于口-肠-肝轴理论探讨微生物传播在代谢相关脂肪性肝病中的作用研究进展[J]. 中国全科医学, 2024, 27(26): 3320-3324. DOI: 10.12114/j.issn.1007-9572.2023.0633.

References 43

[1]	RIAZI K，AZHARI H，CHARETTE J H，et al. The prevalence and incidence of NAFLD worldwide：a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol，2022，7（9）：851-861. DOI：10.1016/S2468-1253(22)00165-0.
[2]	ESLAM M，NEWSOME P N，SARIN S K，et al. A new definition for metabolic dysfunction-associated fatty liver disease：an international expert consensus statement[J]. J Hepatol，2020，73（1）：202-209. DOI：10.1016/j.jhep.2020.03.039.
[3]	肖倩倩，王梦雨，范建高. 亚太肝病研究学会代谢相关脂肪性肝病临床诊疗指南（治疗部分）简介[J]. 临床肝胆病杂志，2021，37（1）：41-45. DOI：10.3969/j.issn.1001-5256.2021.01.009.
[4]	谢娇娇，王莉，何燕芳. 代谢相关脂肪性肝病的发病机制及其与肠道真菌群关系的研究进展[J]. 中国临床新医学，2022，15（8）：765-769. DOI：10.3969/j.issn.1674-3806.2022.08.21.
[5]	MILOSEVIC I，VUJOVIC A，BARAC A，et al. Gut-liver axis，gut microbiota，and its modulation in the management of liver diseases：a review of the literature[J]. Int J Mol Sci，2019，20（2）：395.
[6]	ACHARYA C，SAHINGUR S E，BAJAJ J S. Microbiota，cirrhosis，and the emerging oral-gut-liver axis[J]. JCI Insight，2017，2（19）：e94416. DOI：10.1172/jci.insight.94416.
[7]	WANG B H，JIANG X Y，CAO M，et al. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease[J]. Sci Rep，2016，6：32002.
[8]	ZEYBEL M，ARIF M，LI X Y，et al. Multiomics analysis reveals the impact of microbiota on host metabolism in hepatic steatosis[J]. Adv Sci，2022，9（11）：e2104373. DOI：10.1002/advs.202104373.
[9]	LOOMBA R，SEGURITAN V，LI W Z，et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease[J]. Cell Metab，2019，30（3）：607. DOI：10.1016/j.cmet.2019.08.002.
[10]	YONEDA M，NAKA，NAKANO K，et al. Involvement of a periodontal pathogen，porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease[J]. BMC Gastroenterol，2012，12：16. DOI：10.1186/1471-230X-12-16.
[11]	ARIMATSU K，YAMADA H，MIYAZAWA H，et al. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota[J]. Sci Rep，2014，4：4828. DOI：10.1038/srep04828.
[12]	DING T，SCHLOSS P D. Dynamics and associations of microbial community types across the human body[J]. Nature，2014，509（7500）：357-360. DOI：10.1038/nature13178.
[13]	ATARASHI K，SUDA W，LUO C W，et al. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation[J]. Science，2017，358（6361）：359-365. DOI：10.1126/science.aan4526.
[14]	KURAJI R，SEKINO S，KAPILA Y，et al. Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis：an emerging concept of oral-liver axis[J]. Periodontol 2000，2021，87（1）：204-240. DOI：10.1111/prd.12387.
[15]	LE ROY T，LLOPIS M，LEPAGE P，et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice[J]. Gut，2013，62（12）：1787-1794. DOI：10.1136/gutjnl-2012-303816.
[16]	KIRPICH I A，MARSANO L S，MCCLAIN C J. Gut-liver axis，nutrition，and non-alcoholic fatty liver disease[J]. Clin Biochem，2015，48（13/14）：923-930.
[17]	夏凡，周本杰. 肠-肝轴功能紊乱在非酒精性脂肪肝病发病机制中的作用及相关治疗策略[J]. 世界华人消化杂志，2018，26（24）：1439-1447. DOI：10.11569/wcjd.v26.i24.1439.
[18]	CANI P D，AMAR J，IGLESIAS M A，et al. Metabolic endotoxemia initiates obesity and insulin resistance[J]. Diabetes，2007，56（7）：1761-1772. DOI：10.2337/db06-1491.
[19]	CASLIN B，MOHLER K，THIAGARAJAN S，et al. Alcohol as friend or foe in autoimmune diseases：a role for gut microbiome?[J]. Gut Microbes，2021，13（1）：1916278. DOI：10.1080/19490976.2021.1916278.
[20]	WADE W G. The oral microbiome in health and disease[J]. Pharmacol Res，2013，69（1）：137-143. DOI：10.1016/j.phrs.2012.11.006.
[21]	KONG B，LUYENDYK J P，TAWFIK O，et al. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet[J]. J Pharmacol Exp Ther，2009，328（1）：116-122. DOI：10.1124/jpet.108.144600.
[22]	CLIFFORD B L，SEDGEMAN L R，WILLIAMS K J，et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption[J]. Cell Metab，2021，33（8）：1671-1684.e4. DOI：10.1016/j.cmet.2021.06.012.
[23]	ÅBERG F，HELENIUS-HIETALA J. Oral health and liver disease：bidirectional associations-a narrative review[J]. Dent J，2022，10（2）：16. DOI：10.3390/dj10020016.
[24]	ALBUQUERQUE-SOUZA E，SAHINGUR S E. Periodontitis，chronic liver diseases，and the emerging oral-gut-liver axis[J]. Periodontol 2000，2022，89（1）：125-141. DOI：10.1111/prd.12427.
[25]	CASTANER O，GODAY A，PARK Y M，et al. The gut microbiome profile in obesity：a systematic review[J]. Int J Endocrinol，2018，2018：4095789. DOI：10.1155/2018/4095789.
[26]	HAN P Y，SUN D X，YANG J. Interaction between periodontitis and liver diseases[J]. Biomed Rep，2016，5（3）：267-276. DOI：10.3892/br.2016.718.
[27]	FURUSHO H，MIYAUCHI M，HYOGO H，et al. Dental infection of Porphyromonas gingivalis exacerbates high fat diet-induced steatohepatitis in mice[J]. J Gastroenterol，2013，48（11）：1259-1270. DOI：10.1007/s00535-012-0738-1.
[28]	GHOLIZADEH P，PORMOHAMMAD A，ESLAMI H，et al. Oral pathogenesis of Aggregatibacter actinomycetemcomitans[J]. Microb Pathog，2017，113：303-311. DOI：10.1016/j.micpath.2017.11.001.
[29]	HYVÄRINEN K，TUOMAINEN A M，LAITINEN S，et al. Chlamydial and periodontal pathogens induce hepatic inflammation and fatty acid imbalance in apolipoprotein E-deficient mice[J]. Infect Immun，2009，77（8）：3442-3449. DOI：10.1128/IAI.00389-09.
[30]	KAMATA Y，KESSOKU T，SHIMIZU T，et al. Periodontal treatment and usual care for nonalcoholic fatty liver disease：a multicenter，randomized controlled trial[J]. Clin Transl Gastroenterol，2022，13（11）：e00520. DOI：10.14309/ctg.0000000000000520.
[31]	KURAJI R，SHIBA T，DONG T S，et al. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis[J]. World J Gastroenterol，2023，29（6）：967-996. DOI：10.3748/wjg.v29.i6.967.
[32]	中华预防医学会微生态学分会. 中国微生态调节剂临床应用专家共识（2020版）[J]. 中国微生态学杂志，2020，32（8）：953-965. DOI：10.13381/j.cnki.cjm.202008020.
[33]	WANG Y，XING X Y，MA Y X，et al. Prevention of high-fat-diet-induced dyslipidemia by Lactobacillus plantarum LP104 through mediating bile acid enterohepatic axis circulation and intestinal flora[J]. J Agric Food Chem，2023，71（19）：7334-7347. DOI：10.1021/acs.jafc.2c09151.
[34]	VELAYUDHAM A，DOLGANIUC A，ELLIS M，et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice[J]. Hepatology，2009，49（3）：989-997.
[35]	SHARPTON S R，MARAJ B，HARDING-THEOBALD E，et al. Gut microbiome-targeted therapies in nonalcoholic fatty liver disease：a systematic review，meta-analysis，and meta-regression[J]. Am J Clin Nutr，2019，110（1）：139-149. DOI：10.1093/ajcn/nqz042.
[36]	WANG Y，ZHANG S，BORODY T J，et al. Encyclopedia of fecal microbiota transplantation：a review of effectiveness in the treatment of 85 diseases[J]. Chin Med J，2022，135（16）：1927-1939. DOI：10.1097/CM9.0000000000002339.
[37]	陶永彪，汪龙德，李正菊，等. 肠道菌群代谢物短链脂肪酸改善非酒精性脂肪肝病的作用研究进展[J]. 中国药理学与毒理学杂志，2023，37（1）：47-53. DOI：10.3867/j.issn.1000-3002.2023.01.006.
[38]	李月芹，赵红伟，郑吉敏，等. 粪菌移植对非酒精性脂肪肝大鼠肠黏膜的保护作用[J]. 中国微生态学杂志，2020，32（8）：893-896. DOI：10.13381/j.cnki.cjm.202008006.
[39]	CRAVEN L，RAHMAN A，NAIR PARVATHY S，et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability：a randomized control trial[J]. Am J Gastroenterol，2020，115（7）：1055-1065. DOI：10.14309/ajg.0000000000000661.
[40]	ZHOU D，PAN Q，SHEN F，et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota[J]. Sci Rep，2017，7（1）：1529. DOI：10.1038/s41598-017-01751-y.
[41]	LI G L，XIE C，LU S Y，et al. Intermittent fasting promotes white adipose browning and decreases obesity by shaping the gut microbiota[J]. Cell Metab，2017，26（4）：672-685.e4. DOI：10.1016/j.cmet.2017.08.019.
[42]	韩江，杨燕. 以肠道菌群为靶点的中药改善非酒精性脂肪性肝病的治疗机制研究[J]. 兰州大学学报（医学版），2022，48（2）：74-80. DOI：10.13885/j.issn.1000-2812.2022.02.015.
[43]	GADALETA R M，VAN ERPECUM K J，OLDENBURG B，et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease[J]. Gut，2011，60（4）：463-472. DOI：10.1136/gut.2010.212159.